Adagio Medical (Nasdaq:ADGM) today announced new six-month results from its FULCRUM-VT clinical trial evaluating its ablation ...

In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.

The trial is evaluating the vCLAS cryoablation system at 20 centres across Canada and the US.

SAN FRANCISCO -- Noninvasive stereotactic radiotherapy (RT) for refractory ventricular tachycardia (VT) achieved outcomes similar to catheter ablation with substantially fewer serious adverse events ...

Ventricular tachycardia (VT) is caused by abnormal electrical circuits originating from diseased areas of the ventricular myocardium. It usually results in a rapid heartbeat, preventing effective ...

Directing patients selectively to centers performing higher volumes of ventricular tachycardia (VT) ablation may help reduce in-hospital complications following the procedure, an observational study ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermedical ®, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced today that the U.S. Food & Drug Administration (FDA) has approved an ...

Ablation, a procedure to treat abnormal electrical short circuits caused by a heart attack and is usually reserved for patients who do not improve with medication, may be a better first-line treatment ...

NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...

A technique borrowed from radiation oncology that takes the catheter out of catheter ablation continued to put in an impressive performance, observers say, in the longest yet follow-up of patients ...

Please provide your email address to receive an email when new articles are posted on . Patients with scar-related ventricular tachycardia (VT) who received VT ablation plus a subcutaneous ICD had ...